(Total Views: 340)
Posted On: 07/11/2020 7:46:01 AM
Post# of 72
Some of you may not even be aware of this product: Excellagen
Excellagen is a wound care product. Gene Bio sold the US rights to Excellagen. Generex Biotechnology (GNBT) owns the rights here and has a contract with all 165 VA hospitals. GNBT stock trades at a significant discount to its real value thanks to Covid-19 etc. Anyway, Gene Bio still retains the worldwide rights. I believe eventually as the product gains traction in the US, GB will be able to distribute it elsewhere.
From Chris:
Hi xxxxxx
Many thanks for keeping an eye on us. We continue to work on our financial plan and funding for our Phase 3 clinical study. With respect to Excellagen, we sold Excellagen for $4.0 million. We received $650,000 in cash and we are entitled to $3,350,000 payment based on 10% royalty payment on net commercial sales of Excellagen. Regards, Chris Reinhard
Excellagen is a wound care product. Gene Bio sold the US rights to Excellagen. Generex Biotechnology (GNBT) owns the rights here and has a contract with all 165 VA hospitals. GNBT stock trades at a significant discount to its real value thanks to Covid-19 etc. Anyway, Gene Bio still retains the worldwide rights. I believe eventually as the product gains traction in the US, GB will be able to distribute it elsewhere.
From Chris:
Hi xxxxxx
Many thanks for keeping an eye on us. We continue to work on our financial plan and funding for our Phase 3 clinical study. With respect to Excellagen, we sold Excellagen for $4.0 million. We received $650,000 in cash and we are entitled to $3,350,000 payment based on 10% royalty payment on net commercial sales of Excellagen. Regards, Chris Reinhard
(0)
(0)Scroll down for more posts ▼
